CSN Login
Members Online: 7

You are here

Great news!

CSN is getting an upgrade. All of your posts will still be here, but the website will have a new look, new features and be mobile-friendly. To prepare for the changes, the site will be down briefly at the end November. We’ll continue to provide updates as we get closer.    

Interesting RCC trials with Bristol Meyers

penitent
Posts: 79
Joined: Jun 2016

I don't know if you saw this in the news yesterday, but I found it interesting:

Bristol-Myers Squibb (BMY). A combination of two immunotherapy drugs of the company, Opdivo and Yervoy, cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. The scale of the benefit provided by the two immune system-boosting drugs has been disclosed to experts attending the European Society for Medical Oncology (ESMO) congress in Madrid. Separately, researchers reported that Opdivo is a better and safer option than Yervoy for treating melanoma patients who have had surgery to remove disease.

Supersum's picture
Supersum
Posts: 109
Joined: Aug 2017

Advancements in understanding and treating various types of cancer are increasing in frequency now but it still takes time.

I read the reuters article but I don't understand what this paragraph means for the claimed 37% cut in risk of death:

"In August, Bristol-Myers reported Opdivo and Yervoy failed to significantly outperform standard care in checking cancer progression, although there was a trend toward benefit."

Maybe it is something simple I am overlooking. Does the combination deliver a 37% cut in the risk of death or does it fail to significantly outperform standard care? Or are they not mutually exclusive?

Manufred's picture
Manufred
Posts: 241
Joined: May 2017

I understand that the Reuters press release is talking about publication of the results from the Checkmate 214 trial - see parallel discussion started by Lobbyist 0724, and follow his link to the actual BMS press release. 

There are different reported outcomes for different groupings in the overall trial sample.

I have also responded to that posting with my own experience with these drugs (Yervoy is Ipilimumbab and Opdivo is Nivolumab).  I am considered cured of the Stage 4 mRCC with which I was diagnosed in April 2015, although I am reluctant to take that as a certainty.  I was always symptom free throughout my whole cancer experience, and was reasonably fit and healthy, other than what the sacns were telling us.

I am still receiving the Nivo as part of the trial although that may now change.  I regard these drugs as having saved my life and am very happy to see that others can now get access to it. 

I also think this is a perfect example of what science can achieve, despite the noise from some of the science sceptics out there.

foxhd's picture
foxhd
Posts: 3183
Joined: Oct 2011

I was in a phase one trial of nivo. Before it had a real name it was MDX-1107. It saved me too. 6 years ago.

Darron's picture
Darron
Posts: 310
Joined: Jun 2013

...so I rarely post anymore, but I do creep in and read, pray for lots more than I speak about.I am also a phase I of the trial. I am still in the Sutent -Nivo arm of the trial. It will be 5 years in February that I have been taking the combo. Still here, still cancer free.

Subscribe to Comments for "Interesting RCC trials with Bristol Meyers"